Photo of Barrie Weinstein

Barrie Weinstein

  • ASSISTANT PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
Print ProfilePrint Profile


    Barrie M. Weinstein, MD, CCD joined the faculty at The Mount Sinai Medical Center in July. 2010 with an appointment in the Division of Endocrinology.  She is a board-certified endocrinologist, internist and nutrition-support physician.  After graduating from the Sackler School of Medicine in Tel Aviv, Israel, she completed her Internship and Residency in Internal Medicine at The Mount Sinai School of Medicine.  After completing her Residency in 2007, she served as a post-doc research fellow at Mount Sinai in the Division of Endocrinology, where she focused on the effects of COX-2 inhibitors and PGE2 on bone.  She then completed a fellowship in Endocrinology, Diabetes and Bone Disease at the Mount Sinai Medical Center, graduating in 2010. 

    Dr. Weinstein is part of the Bone Densitometry Program at Mount Sinai, interpreting bone density reports.


Weinstein BM, Epstein S. Drug and hormone effects on Vitamin D metabolism. In: Feldman D, Pike JW, Adams JS, editors. Vitamin D, Third Edition.. Academic Press; 2011.; pp1245-1290.

Weinstein BM, Kirschenbaum A, Janout V, Regen SL, Yao S, Levine AC. Development of New Compounds Specifically Targeting Prostate Cancer Bone Metastases. .;.

Liu XH, Kirschenbaum A, Weinstein BM, Zaidi M, Yao S, Levine AC. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells. Biochemical and biophysical research communications 2010 Apr; 394(3).

Weinstein BM, Levine AC, Kim M, Skamagas M. Adrenal Histoplasmosis Diagnosed by Endoscopic Ultrasound Guided FNA of the Left Adrenal: A Review of the Literature of Histoplasmosis of the Adrenals and EUS-guided FNA..;.

Weinstein BM, Liu X, Yao S, Kirschenbaum A, Levine AC. Dose-Dependent Effects of PGE2 on Osteoblasts: Implications for Osteoporosis Treatment..;.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Weinstein did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Atran Berg Laboratory Building Floor 4th floor Room AB4-31
1428 Madison Avenue
New York, NY 10029

Tel: 212-241-7975